News and Events / Media

From the CEO's Desk

Swaroop Vakkalanka, PhD

Founder & CEO

My tryst with biotech R&D has been exciting and mutually rewarding in the last 25 years. There is a constant need for innovative therapies that could influence human lives positively.

Rhizen Pharma was founded with a vision to discover and develop novel onco-therapeutics designed to improve the quality of life of patients and drive transformative outcomes.

Rhizen is deeply committed to fulfilling this vision to address the immense unmet need that exists for patients living with cancer.

At Rhizen we practice

Fostering a culture of cutting-edge innovation as has been evidenced by our pivotal leadership in the “Targeted Drugs for Oncology” space through our focus on selective PI3K inhibitors with pathbreaking differentiation

Staying focused on the patient care with a relentless drive; tracking the evolution of cancer biology and explore remedies for challenges thrown

Creative collaboration and partnerships across global markets and research institutes

Purposeful communication to ensure the team’s focus on imaginative outcomes As we head into 2025 with aspirations to grow as full-fledged Oncology development and commercialization company,

I firmly believe we are poised to make tangible difference to cancer care and to potentially bring to market innovative medicines. This is at the core of our philosophy and shapes the values at our company.

Latest News

Now Approved - Rhizen Pharma’s partnered asset Umbralisib has received US FDA accelerated approval for relapsed/refractory MZL and FL.

Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020

LA CHAUX DU FONDS, Switzerland--(BUSINESS WIRE)--Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S.

Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China

Exclusive licensing agreement for the development and commercialization of Tenalisib, a dual PI3K delta & gamma inhibitor in the Greater China region.

To read more about Rhizen in the News, click here

Recent Publications

Preclinical profile of RP12146, a novel, selective, and potent small molecule inhibitor of PARP1/2

543: Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study. (ASH 2020)

UNITY-CLL is the first randomized Phase 3 study in CLL of a PI3Ki vs. chemoimmunotherapy, and the first randomized study of a PI3Ki in treatment-naive CLL.

1155: A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma (ASH 2020)
The combination of tenalisib and romidepsin demonstrates a favorable safety profile and promising indicators of combined anti-tumour activity in patients with R/R TCL.

To read more about Rhizen in the Publications, click here

The Rhizen Blog

Coming Soon!